The firm saw an increase in diagnostics solutions sales in the second quarter, particularly within its QuantiFeron and QiaStat-Dx businesses.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

The firm anticipates lower-than-previously-expected COVID test sales will be offset by shifts in trade policy and tariff mitigation efforts.